Skip to main content

Peter Maag

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Peter Maag

Earlier roles on record: CEO at Kyverna Therapeutics, Inc. (KYTX) until September 16, 2024. Kyverna Therapeutics, Inc. reported in an 8-K filed September 16, 2024 that Peter Maag resigned as member of the Board, effective September 16, 2024. Kyverna Therapeutics, Inc. reported in an 8-K filed September 16, 2024 that Peter Maag resigned as CEO, effective September 16, 2024. Kyverna Therapeutics, Inc. reported in an 8-K filed September 16, 2024 that Peter Maag resigned as all positions that you held with the Company or any of its subsidiaries and affiliates, including, without limitation, as an emp, effective September 13, 2024. Equibles holds 6 filed executive changes naming Peter Maag; each is listed under recent activity with its source filing. The proxy statement of Kyverna Therapeutics, Inc. reports total compensation of $1,481,230 for Peter Maag in fiscal 2024, including a base salary of $786,466. Peter Maag has spoken on 1 investor event across 1 company, most recently for Kyverna Therapeutics, Inc. on June 3, 2026.

“Mr. Biddle succeeds Peter Maag, Ph.D., who has resigned from his role as CEO and a member of the Board, effective immediately.”
Kyverna Therapeutics, Inc. Form 8-K, filed September 16, 2024 · Read the filing
“Mr. Biddle succeeds Peter Maag, Ph.D., who has resigned from his role as CEO and a member of the Board, effective immediately.”
Kyverna Therapeutics, Inc. Form 8-K, filed September 16, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 Kyverna Therapeutics, Inc. (KYTX) $786,466 $1,481,230

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.